Effectively, if further in vitro investigations followed by pre-clinical studies in animal models of COVID-19 prove that auranofin can inhibit NF-κB-induced IL-6 expression as well as SARS-CoV-2 replication and SARS-CoV-2 papain-like protease, auranofin could become a valuable addition to available therapies for COVID-19. The gene discussed is NFKB1; the disease is COVID-19.